These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 27069256)

  • 1. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
    Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
    Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
    Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
    Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
    Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M
    Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
    Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
    Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
    Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
    Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
    Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
    Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
    Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
    Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
    Ahn IE; Davids MS
    Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
    Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
    Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
    Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
    Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
    Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
    Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
    Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
    Crombie J; Davids MS
    Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
    N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.
    Seyfried F; Demir S; Hörl RL; Stirnweiß FU; Ryan J; Scheffold A; Villalobos-Ortiz M; Boldrin E; Zinngrebe J; Enzenmüller S; Jenni S; Tsai YC; Bornhauser B; Fürstberger A; Kraus JM; Kestler HA; Bourquin JP; Stilgenbauer S; Letai A; Debatin KM; Meyer LH
    Cell Death Dis; 2019 Jul; 10(8):571. PubMed ID: 31358732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.